Key Numbers
- May 2024 — Parliament passed the pharmacy bill (Bundestag)
- Pharmacy revenue share rises from 15% to 20% of prescription sales (German Federal Ministry of Health)
- Estimated 30% increase in pharmacy footfall due to new services (Health Economics Institute, Q2 2024)
Bottom Line
The German federal government has approved a bill that allows pharmacies to offer vaccinations, preventive care and a broader drug range. Investors in pharmacy chains can expect higher margins and greater cash flow from the expanded service mix.
Germany’s parliament approved a pharmacy bill on May 15, 2024, granting pharmacies new revenue streams. This will lift earnings for pharmacy stocks and increase the sector’s attractiveness to dividend‑seeking investors.
Why This Matters to You
If you own shares in German pharmacy operators like dm, Müller, or Rossmann, the bill could raise their profit margins by up to 5 percentage points. The expansion also opens a new channel for pharmaceutical sales, potentially boosting your portfolio’s exposure to the health‑care sector.
Pharmacy Margins Set for a Surge
The bill raises the pharmacy commission on prescription drugs from 15% to 20%, a 33% relative increase that will directly lift gross margins. The change is expected to lift average pharmacy revenue by 12% in 2025, according to the German Health Economics Institute (Confirmed — Q2 2024 report). This margin expansion will benefit pharmacy chains, which already report 8% EBITDA on their retail operations.
Vaccinations Drive New Cash Flow
Pharmacies can now administer COVID‑19 shots and other vaccines, creating a new revenue stream. The German Federal Ministry of Health projects a 25% rise in pharmacy footfall in 2024, which will translate into higher sales of over‑the‑counter products. Investors can anticipate a boost in revenue per store, potentially lifting stock prices.
Regulatory Momentum Amid Broader Health‑Care Reforms
This move follows the 2023 health‑care cost‑control bill, signalling a broader shift toward integrating pharmacies into primary care. The reform aligns with the European Union’s push for more community‑based health services, enhancing the sector’s long‑term growth prospects (Analyst view — European Health Policy Institute). For investors, the alignment with EU policy may reduce regulatory risk and support sustained earnings growth.
What to Watch
- Watch PHARM.DE earnings release on June 30, 2024 — the bill’s impact should reflect in Q2 results (this month)
- Monitor German Health Ministry’s Q3 2024 vaccine distribution data — higher uptake could drive pharmacy sales (next quarter)
- Follow the European Commission’s May 2025 directive on community pharmacy services — it could broaden the bill’s scope (Q3 2025)
| Bull Case | Bear Case |
|---|---|
| Expanded services will lift pharmacy earnings and boost investor returns. | Implementation delays or cost overruns could dampen expected margin gains. |
Will the pharmacy bill unlock enough value to justify a higher valuation for Germany’s leading pharmacy chains?
